Compounding Oversight May Hinge On How FDA Treats Office Stock
Pew asks FDA to look at large-scale compounders of office stocks and help encourage them to register, but IACP argues regulation of the office stock should remain with the states.
You may also be interested in...
US agency's budget authority would remain at current level under FY 2018 appropriations bill reported out by a House subcommittee; measure includes language enabling FDA's Oncology Center of Excellence to receive 21st Century Cures funding transferred from National institutes of Health.
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.